• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

    2/23/23 4:17:54 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LMDX alert in real time by email
    SC 13D/A 1 d400811dsc13da.htm SC 13D/A SC 13D/A

    CUSIP No. G5709L 109

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    LumiraDx Limited

    (Name of Issuer)

    Common Shares, par value $0.0000028 per share

    (Title of Class of Securities)

    G5709L 109

    (CUSIP Number)

    Morningside Venture Investments Limited

    C/O THC Management Services S.A.M.,

    2nd Floor,

    Le Prince De Galles

    3-5 Avenue Des Citronniers

    Monaco, MC 98000

    011-377-97-97-47-37

    with a copy to:

    Morningside Technology Advisory, LLC

    Attn: Daniel White, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    July 21, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      Morningside Venture Investments Limited

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      WC

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      British Virgin Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Consists of (i) 17,936,854 common shares, par value $0.0000028 per share (“Common Shares”) of the Issuer held by the Morningside Venture Investments Limited (“MVIL”), (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding ordinary shares held by MVIL, which may be voluntarily converted on a one-to-one basis to Common Shares at any time (“Ordinary Shares”), (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 9,528,124 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the Securities and Exchange Commission (the “SEC”) on December 16, 2022.


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      MVIL, LLC

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      WC

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      11,105,955 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      11,105,955

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,105,955

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      7.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Consists of (i) 9,528,124 Common Shares of the Issuer, and (ii) 1,577,831 Common Shares issuable upon the exercise of warrants of the issuer.

    (2)

    Based on 152,634,554 Common Shares outstanding on December 15, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      Frances Anne Elizabeth Richard

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 17,936,854 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 9,528,124 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      Jill Marie Franklin

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 17,936,854 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 9,528,124 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      Peter Stuart Allenby Edwards

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 17,936,854 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 9,528,124 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      Cheung Ka Ho

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      Hong Kong

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 17,936,854 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 9,528,124 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      Cheng Yee Wing Betty

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      New Zealand

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      11,105,955 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      11,105,955

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,105,955

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      7.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 9,528,124 Common Shares of the Issuer held by MVIL, LLC, and (ii) 1,577,831 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109      

     

      (1)    

      Names of Reporting Persons

     

      Wong See Wai

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      Hong Kong

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      11,105,955 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      11,105,955

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,105,955

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      7.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 9,528,124 Common Shares of the Issuer held by MVIL, LLC, and (ii) 1,577,831 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

    Explanatory Note

    This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on February 14, 2023 (the “Initial Statement”) to correct the ownership by MVIL of shares attributed to MVIL, LLC in the Initial Statement. Except as otherwise noted herein, the information in the Initial Statement is unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    The last paragraph of Item 3 is hereby restated as follows:

    On July 21, 2022, MVIL acquired 10,336,570 Common Shares in a public offering of Issuer for an aggregate purchase price of approximately $18.1 million. All such shares were acquired with working capital.

     

    Item 5.

    Interest in Securities of the Issuer.

    Subsections A, B, G and H of Item 5 are hereby restated as follows:

     

    A.

    Morningside Venture Investments Limited

     

    (a)

    As of the date hereof, MVIL beneficially owns 54,127,838 shares of Common Shares, representing a beneficial ownership of approximately 30.2% of the Common Shares. MVIL directly holds (i) 17,936,854 Common Shares, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares, and (iii) 788,909 Common Shares issuable upon the exercise of warrants, and MVIL, LLC, its wholly owned subsidiary, holds 9,528,124 Common Shares and 1,577,831 Common Shares issuable upon exercise of warrants.

     

    (b)      1.      Sole power to vote or direct vote:      -0-  
         2.      Shared power to vote or direct vote:      54,127,838  
         3.      Sole power to dispose or direct the disposition:      -0-  
         4.      Shared power to dispose or direct the disposition:      54,127,838  

    B. MVIL, LLC

     

    (a)

    As of the date hereof, MVIL, LLC beneficially owns 11,105,955 shares of Common Shares, representing a beneficial ownership of approximately 7.2% of the Common Shares.

     

    (b)      1.      Sole power to vote or direct vote:      -0-  
         2.      Shared power to vote or direct vote:      11,105,955  
         3.      Sole power to dispose or direct the disposition:      -0-  
         4.      Shared power to dispose or direct the disposition:      11,105,955  

     

    G.

    Cheng Yee Wing Betty

     

    (a)

    As of the date hereof, Ms. Cheung beneficially owns 11,105,955 shares of Common Shares, representing a beneficial ownership of approximately 7.2% of the Common Shares.

     

    (b)      1.      Sole power to vote or direct vote:      -0-  
         2.      Shared power to vote or direct vote:      11,105,955  
         3.      Sole power to dispose or direct the disposition:      -0-  
         4.      Shared power to dispose or direct the disposition:      11,105,955  


    CUSIP No. G5709L 109

     

    H.

    Wong See Wai

     

    (a)

    As of the date hereof, Mr. Cheung beneficially owns 11,105,955 shares of Common Shares, representing a beneficial ownership of approximately 7.2% of the Common Shares.

     

    (b)

         1.      Sole power to vote or direct vote:      -0-  
         2.      Shared power to vote or direct vote:      11,105,955  
         3.      Sole power to dispose or direct the disposition:      -0-  
         4.      Shared power to dispose or direct the disposition:      11,105,955  

     

    Item 7.

    Material to be Filed as Exhibits.

    The following documents are filed as Exhibits to this statement:

     

    Exhibit
    Number

      

    Exhibit Description

    99.1    Joint Filing Agreement.


    CUSIP No. G5709L 109

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

    Dated: February 23, 2023

     

    For and on behalf of
    MORNINGSIDE VENTURE INVESTMENTS LIMITED
    By:   /s/ Frances Anne Elizabeth Richard
      Frances Anne Elizabeth Richard, Director

     

    For and on behalf of
    MVIL, LLC
    By:   /s/ Cheng Yee Wing Betty
      Cheng Yee Wing Betty, Manager
    /s/ Frances Anne Elizabeth Richard
    Frances Anne Elizabeth Richard
    /s/ Jill Marie Franklin
    Jill Marie Franklin
    /s/ Peter Stuart Allenby Edwards
    Peter Stuart Allenby Edwards
    /s/ Cheung Ka Ho
    Cheung Ka Ho
    /s/ Cheng Yee Wing Betty
    Cheng Yee Wing Betty
    /s/ Wong See Wai
    Wong See Wai

     

    Get the next $LMDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMDX

    DatePrice TargetRatingAnalyst
    3/11/2022$13.00 → $9.00Outperform
    Raymond James
    11/15/2021$20.00Outperform
    Evercore ISI Group
    10/27/2021$12.00Buy
    BTIG Research
    10/25/2021$13.00Outperform
    Raymond James
    More analyst ratings

    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James reiterated coverage on LumiraDx with a new price target

    Raymond James reiterated coverage of LumiraDx with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

    3/11/22 7:22:18 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Evercore ISI Group initiated coverage on LumiraDx with a new price target

    Evercore ISI Group initiated coverage of LumiraDx with a rating of Outperform and set a new price target of $20.00

    11/15/21 8:56:20 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BTIG Research initiated coverage on LumiraDx with a new price target

    BTIG Research initiated coverage of LumiraDx with a rating of Buy and set a new price target of $12.00

    10/27/21 8:35:45 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

    LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

    1/5/24 5:45:23 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

    LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

    12/29/23 4:15:50 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

    LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimu

    10/27/23 4:45:02 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    SEC Filings

    View All

    SEC Form 6-K filed by LumiraDx Limited

    6-K - LumiraDx Ltd (0001685428) (Filer)

    2/6/24 4:34:15 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 6-K filed by LumiraDx Limited

    6-K - LumiraDx Ltd (0001685428) (Filer)

    12/29/23 4:26:15 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 6-K filed by LumiraDx Limited

    6-K - LumiraDx Ltd (0001685428) (Filer)

    12/8/23 7:15:38 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Financials

    Live finance-specific insights

    View All

    LumiraDx Reports Second Quarter 2023 Results

    LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 millionSubmitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra testSubmitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH's Independent Test Assessment (ITAP) programMore than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory season Ron Zwanziger, Chairman and CEO of LumiraD

    8/24/23 7:45:00 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

    LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 AM Eastern Time   Live Call/Webcast:   Register to join by phone here.  View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar    A replay of the webcast will be available on the Inv

    8/16/23 4:30:00 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Reports First Quarter 2023 Results

    LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.Cost reduction programs implemented across the global organization resulting in declining operating losses.US Clinical Studies for first 510K submission completed.More than 100 customers in the first full launch quarter for the world's first quantitative finger stick NT-proBNP assay. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "Our transition to non-COVID is beginning to develop, especially with the commercial launches of HbA1c

    5/16/23 7:45:00 AM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Leadership Updates

    Live Leadership Updates

    View All

    LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

    LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

    1/5/24 5:45:23 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

    LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

    12/29/23 4:15:50 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

    SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

    2/12/24 4:06:57 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

    SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

    2/9/24 4:16:20 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

    SC 13D/A - LumiraDx Ltd (0001685428) (Subject)

    12/29/23 1:52:49 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care